Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.91 USD
-0.71 (-1.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $39.00 +0.09 (0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMCR 38.91 -0.71(-1.79%)
Will IMCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMCR
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
5 Biotech Stocks to Consider for Your Portfolio in 2024
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
Other News for IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Warning: IMCR is at high risk of performing badly
The Galien Foundation Announces 2024 International Prix Galien and Prix Galien Italy Award Winners
Yellowstone Biosciences launches with #16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma